Source - SMW
Verona Pharma said it expected to collect data from clinical trials of a treatment for chronic obstructive pulmonary disease earlier than it had originally anticipated.

Top-line data from a Phase 2b clinical trial of nebulized RPL554 for maintenance treatment was expected to be reported in the second quarter of 2018, compared to previous guidance of mid-2018, the company said.

Top-line data from a Phase 2a pharmacokinetic and pharmacodynamic clinical trial of RPL554 was expected late in the first quarter, compared to previous guidance of the first half of 2018.

'We are pleased to be making excellent progress in these important studies,' said chief executive Jan-Anders Karlsson.

'We have completed the clinical phase of both studies ahead of schedule and now look forward to reporting top-line data sooner than our previous guidance.'


At 1:05pm: (LON:VRP) Verona Pharma PLC share price was +3.5p at 106p



Related Charts

Verona Pharma (VRP)

0.00p (0.00%)
delayed 08:34AM